2.50 -0.01 (-0.40%)
After hours: 6:09PM EST
|Bid||2.50 x 800|
|Ask||2.63 x 900|
|Day's Range||2.5000 - 2.7500|
|52 Week Range||2.3500 - 10.6500|
|Beta (3Y Monthly)||3.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.67|
Sorrento Therapeutics, Inc. (SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150 million. The financing is being provided by funds and accounts managed by Oaktree Capital Management, L.P. (“Oaktree”), a leading global investment firm.
Sorrento Therapeutics, Inc. (SRNE) ("Sorrento") announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for Metastases (HITM-SURE) clinical trial results will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 7-11 in Washington, DC. Five patients, four pancreatic and one colorectal, with carcinoembryonic antigen–positive (CEA+), unresectable stage IV adenocarcinoma with liver metastases, who had failed one or more lines of systemic chemotherapy, each received three hepatic artery infusions of Sorrento autologous anti-CEA CAR-T cells using the Hepatic Immunotherapy for Metastases (HITM) method.
Sorrento Therapeutics, Inc. (SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple myeloma patients at two clinical sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manufactured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study. This study is the first US-based clinical trial targeting CD38 using an autologous CAR-T cell therapy.
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The stock market - especially growth stocks - is at an interesting inflection point as we enter the final quarter of 2018. On the one hand, the Standard & Poor's 500-stock index recovered from a tumultuous midyear with a 7% third-quarter gain that marked its best quarterly performance since 2013. On the other, interest-rate worries have sent a quick scare into the markets, and riskier, growth-oriented equities have suffered a bit of a pullback. Still, corporate earnings have impressed, unemployment remains at multi-decade lows and the economy is growing. So as we head into the seasonally strong fourth quarter, the question for anyone who still believes the broader trend is up becomes, "Which stocks are Wall Street analysts singling out as compelling investing opportunities?" We can use TipRanks to pinpoint top growth stocks - as identified by Wall Street's brightest minds - that have significant growth potential. Let's take a closer look at these 10 top picks now: SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (SRNE) (Sorrento), announced that ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is now commercially available. ZTLIDO will be shipped to wholesalers and is anticipated to be available by prescription at retail pharmacies across the U.S. by the end of this week, thus commencing a full U.S. launch. Scilex has entered into an agreement with Syneos Health (formerly, Inventiv Health) to support the launch and commercialization of ZTLIDO in the U.S. ZTLIDO is supported by an experienced, field sales team of over a hundred sales representatives, as well as Medical Science Liaison (MSL), market access and trade teams. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus which afflicts an estimated 1 million people each year in the US.
SAN DIEGO, Sept. 27, 2018-- Sorrento Therapeutics, Inc, a clinical stage, antibody-centric, biopharmaceutical company developing new therapies today announced that Henry Ji Ph.D,, Chairman, President and ...
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus, which afflicts an estimated 1 million people each year in the US.
- Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 - Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles ...
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares were rallying Monday following the announcement of positive trial results for its osteoarthritis knee pain treatment candidate. In pre-market trading, the ...
NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Ampio Pharmaceuticals and Sorrento Therapeutics both saw big moves in opposite directions on Friday. Ampio Pharmaceuticals, Inc. shares closed up 11.44% on Friday with trading volume roughly three times higher than usual at 2,251,564 shares traded. It was recently revealed that Susquehanna International Group Llp has increased its position in the stock by $57,249.
LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.
Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules. Striving to catch up with New York and Shanghai as an IPO hotspot, the Hong Kong Stock Exchange announced new policies late last year that actively court biotech companies, including those that do not have a drug on the market.
When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent. Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules.
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).